news flash·2025-06-18 10:22Core Viewpoint - China Biopharmaceutical announced the results of preclinical and Phase Ib clinical studies for Rovadicitinib in treating acute graft-versus-host disease (aGVHD) at the 2025 European Hematology Association (EHA) annual meeting, highlighting a significant overall response rate (ORR) of 84.6% over 28 days and a median response time of 4 days, with a 12-month overall survival rate of 92.3% [1] Group 1 - Rovadicitinib is an oral, selective JAK1/2 and ROCK1/2 inhibitor targeting multiple pathways in aGVHD, potentially offering better treatment options for steroid-refractory (SR) aGVHD patients [1] - The drug is the first global JAK/ROCK dual-pathway inhibitor, marking a breakthrough in the treatment of graft-versus-host disease (GVHD) [1] - A Phase III clinical trial for Rovadicitinib in treating chronic graft-versus-host disease (cGVHD) has been initiated, currently in the subject enrollment phase [1]